Chemical Synthesis of Insulins

The members from the lab of Richard DiMarchi have recently published a very comprehensive review (http://onlinelibrary.wiley.com/doi/10.1002/psc.2863/abstract) about the chemical synthesis of peptides from the insulin super family. As everyone knows, insulin peptides represent some of the toughest molecules to synthesize due to the presence of both intra- and intermolecular disulfide bonds linking the A and B chains. Additionally, syntheses of the two chains are not trivial, nor is their reconstitution in the appropriate oxidative folding buffers. In this review, Liu, et al., present a historical overview of the chemical methods developed in the early 1960’s up to the present culminating with their improved strategies for making insulin in one pot as well as coverage of synthesis of insulin like peptides such as IGF-II and relaxin. For those of us interested in disulfide rich peptides, this is an excellent review especially for making these bonds sequentially.

Custom Peptide Synthesis , Industry News , Biologically Active Peptides

Dr. Michael W. Pennington

See all articles from Dr. Michael W. Pennington

Dr. Michael Pennington joined Peptides International in December 2010 as Chief Technology Officer. On January 1, 2013, Dr. Pennington's role became that of President and Chief Executive Officer. After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough. He joined Bachem Biosciences in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. Dr. Pennington served as the Group Director for Bachem Biosciences before being appointed as President and C.O.O., a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc., a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases. Dr. Pennington has been awarded four patents and over 85 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelor of Chemistry degree from the University of North Carolina at Chapel Hill and a Ph.D. from University of Florida at Gainesville.